NanoViricides highlights broad-spectrum antiviral strategy and progress with lead drug candidate

NanoViricides Chief Financial Officer Meeta Vyas joined Steve Darling from Proactive to share updates on the company’s development of broad-spectrum antiviral therapeutics and its unique positioning amid global market uncertainty. Vyas emphasized that NanoViricides, headquartered in Shelton, Connecticut, conducts all of its research and development in-house, which insulates the company from international tariff fluctuations and supply chain disruptions. At the center of the company’s pipeline is NV-387, a broad-spectrum antiviral drug that differs from vaccines in both function and strategy. Rather than targeting specific viral strains, NV-387 works by mimicking the receptor sites used by over 90% of pathogenic viruses—including influenza, RSV, COVID-19, and smallpox. Vyas explained that this approach helps circumvent the problem of viral mutation, which often renders traditional vaccines less effective. “Regardless of how they mutate, they land on the same receptor site. So we copy the receptor site, which is invariant to mutation,” she said, underscoring the robustness of the NanoViricides platform. She also highlighted supportive regulatory developments in the U.S., noting that the new HHS administration has endorsed a more integrated approach to pandemic preparedness, which includes therapeutics like NV-387 as a key component. In light of recent USDA funding initiatives aimed at combating H5N1 avian flu, Vyas said the company is keen to explore applications of NV-387 in that space as well. Currently, NanoViricides is conducting a Phase 2 clinical trial targeting smallpox, following successful Phase 1 results with no reported adverse effects. #proactiveinvestors #nanoviricidesinc #nyseamerican #nnvc NV387 #BroadSpectrumAntiviral #BiotechStocks #AntiviralTherapeutics #SmallpoxTreatment #BirdFlu #RSV #COVID19Treatment #ProactiveInvestors #PharmaInnovation #MeetaVyas #HHS #PandemicPreparedness

Solvonis Therapeutics PLC (LSE:SVNS) CEO Anthony Tennyson talked with Proactive about the company's strategic move to commercialise two clinical-stage assets targeting alcohol use disorder (AUD). Tennyson explained that Solvonis has engaged PharmaVentures to support valuation and potential out-licensing for two lead programs—AWKN-001 and AWKN-002. PharmaVentures was chosen based on its three-decade track record in biopharma M&A advisory, with over 1,000 deals completed. Tennyson noted, “We’ve selected them for three reasons: their expertise, their experience, and their reach.” The two assets originated from Solvonis's planned acquisition of Awakn Life Sciences, a transaction expected to be completed in the second quarter. AWKN-001, now in Phase 3 trials, targets severe AUD in the UK and EU. PharmaVentures estimates the asset could yield around £60 million in upfront and milestone payments, plus significant double-digit royalties. AWKN-002, focused on moderate to severe AUD in the US, is in Phase 2B planning. This program could generate approximately £150 million, based on comparable transactions. Tennyson emphasised the unmet medical need, citing a 75% relapse rate within a year for current AUD treatments. “That represents a significant commercial opportunity for Solvonis,” he said. For more interviews like this, visit Proactive's YouTube channel. Give this video a like, subscribe, and enable notifications to stay updated. #SolvonisTherapeutics #AlcoholUseDisorder #BiotechNews #ClinicalTrials #AWKN001 #AWKN002 #AddictionTreatment #PharmaVentures #MentalHealthInnovation #BiopharmaDeals #InvestorUpdate #HealthcareStocks #Phase3Trial #Outlicensing #Q2Milestones

4GLOBAL PLC (AIM:4GBL) CEO Eloy Mazon talked with Proactive's Stephen Gunnion about the company’s expanded agreement with Sport England. The updated contract deepens 4GLOBAL’s role in delivering data-led insights to support increased sports participation across England, extending beyond facilities to include outdoor and informal activity spaces. Mazon explained that this new phase builds on a successful four-year partnership which helped boost participation by over 30%. “We like to think we play a very significant part in achieving those outcomes,” he said, referring to the impact of 4GLOBAL’s data platform on investment decisions in grassroots sports. Now, Sport England is shifting focus to track physical activity beyond formal facilities, such as cycling paths and running tracks. 4GLOBAL’s recently launched insight platform plays a key role by integrating multiple datasets to generate predictive insights. Mazon said, “This contract…places us at the centre of sport and physical activity in England.” He added that the broader ecosystem engagement—covering everything from local authorities to gym operators—offers not only data value for Sport England but commercial opportunities for 4GLOBAL. Mazon also highlighted the strategic value of this multi-year, multi-million-pound contract as part of the company’s move toward recurring revenue and EBITDA growth. “The focus for us going forward is to really grow EBITDA, because that provides us with that free cash flow…to invest in growth,” he noted. For more CEO interviews and market updates, head to Proactive's YouTube channel. Don’t forget to like this video, subscribe to the channel, and turn on notifications for the latest updates. #4GLOBAL #SportEngland #DataAnalytics #PhysicalActivity #GrassrootsSports #SportsInvestment #ARRGrowth #EBITDA #SmartData #ProactiveInvestors #UKSport

Zynex Medical Executive Vice President of Sales Steve Fox joined Steve Darling from Proactive to discuss the company’s commitment to noninvasive, non-addictive at-home pain management through its flagship device, NexWave. Fox highlighted how Zynex Medical is tackling the opioid crisis by providing alternative pain solutions that empower both healthcare providers and patients. The NexWave device integrates three key modalities—TENS (Transcutaneous Electrical Nerve Stimulation), IFC (Interferential Current), and NMES (Neuromuscular Electrical Stimulation)—making it a versatile tool for post-operative recovery and long-term pain management. “Most providers are really on board with a device like this because it’s very universal,” Fox explained. A crucial aspect of Zynex’s strategy is education, with nearly 300 sales representatives across the U.S. working to inform healthcare providers about alternatives to opioid prescriptions. While the company’s focus remains on the domestic market, Fox noted significant untapped potential within the United States. Fox also spoke about Zynex’s strong internal culture, emphasizing the team’s alignment around a shared mission. “It’s our mission to provide an at-home pain management treatment option that’s noninvasive, non-addictive. That won’t change,” he said, highlighting the passion and unity that continue to drive the company’s growth. #proactiveinvestors #nasdaq #zyxi #zynexinc #NexWave #PainManagement #OpioidAlternative #MedicalDevices #NonInvasiveTherapy #NMES #TENS #HealthcareInnovation #ProactiveInvestors

Andromeda Metals Ltd acting CEO Sarah Clarke talked with Proactive about the company's progress on its flagship Great White Project in South Australia. Clarke outlined how the company is nearing a critical funding milestone, having entered into exclusive negotiations with Merricks Capital for a debt financing facility of up to $75 million. She explained that this follows detailed due diligence and represents a significant advancement in the project’s development. She noted that the facility would cover capitalised interest, fees, and a cost overrun tranche, with exclusivity on negotiations running through to the end of July. Clarke also said Andromeda is pursuing the balance of required funds through a parallel equity or investment process. The Great White Project is a high-grade kaolin operation targeting premium ceramic markets and sustainable concrete products. The company has all key approvals in place, feasibility studies completed, long-lead items ordered, and binding offtake agreements secured for its Stage 1A+ development, which involves 100,000 tonnes of kaolin production per annum. Clarke said the project team is fully mobilised, working across both operational readiness and financing, to ensure rapid commencement of construction once funding is secured. Visit Proactive’s YouTube channel for more videos, and don’t forget to give the video a like, subscribe to the channel and enable notifications for future content. #AndromedaMetals #GreatWhiteProject #Kaolin #MiningAustralia #CriticalMinerals #CeramicsIndustry #GreenConcrete #ProjectFinancing #MerricksCapital #ProactiveInvestors

Element 25 managing director Justin Brown talked with Proactive about the recent completion of the Tokyo Bay HPMSM Facility Scoping Study in partnership with Nissin Chemical Corporation. The company said the results of the scoping study were positive enough to justify advancing the project to the pre-feasibility stage. Brown explained that the Tokyo Bay site offers unique advantages, including a co-located sulfuric acid plant, deepwater port access, and supporting infrastructure critical for high-purity manganese sulfate production. “We took our learnings from the detailed work we’ve done in Louisiana… and converted them to a Japanese setting,” Brown said. He also noted that Japan's regulatory and geopolitical environment makes it an ideal location for refining and supplying the local battery market. Looking ahead, Brown confirmed that Element 25 and Nissin Chemical will conduct deeper engineering and cost analysis under their existing MOU, with a final investment decision targeted for June 2026. The next milestone will be the pre-feasibility study, expected later this year. Brown also discussed how the Tokyo Bay project fits into the company’s broader “design one, build many” strategy, which aims to establish a global network of refineries fed by ethically sourced manganese from Element 25’s Butcherbird mine. In addition to activity in Japan, Brown highlighted ongoing work in Europe and updates on the Butcherbird expansion and Louisiana project, with construction planned to commence later this year. For more interviews like this, visit Proactive’s YouTube channel. Don’t forget to like the video, subscribe to the channel, and turn on notifications so you never miss an update. #Element25 #Manganese #BatteryMetals #TokyoBay #CriticalMinerals #EVSupplyChain #HPMSM #ButcherbirdProject #CleanEnergyMaterials #JapanRefinery #MiningNews #GreenMetals #ProactiveInvestors

Race Oncology CEO and MD Daniel Tillett talked with Proactive about the opening of patient enrollment at the first Australian clinical site for the RC220 Phase I solid tumour trial. Tillett confirmed that the trial is now underway, with additional sites expected to follow soon. The focus of this early-stage study is to determine a safe and effective combination dose of RC220 with the chemotherapy drug doxorubicin. According to Tillett, “our drug has the advantage… not only does it improve the anti-cancer treatment, but it protects the heart, at least in animals and cells to date.” He noted the choice of Southside Cancer Centre as the initial site, citing the faster startup process compared to public hospitals. Other sites, including Gosford and Wyong, have also received ethics approval and are expected to join the trial following regulatory clearance. Tillett discussed the use of a Bayesian trial design, which allows quicker progression and minimises patient exposure to suboptimal doses. While this approach can introduce uncertainty in timelines, it is expected to be more beneficial overall for patients and the company. Early preclinical data has shown that RC220 can reduce doxorubicin-related toxicity while enhancing cancer treatment outcomes, a combination Tillett described as unique among current therapies. Beyond the trial, Race Oncology is conducting separate preclinical studies to identify the most effective drug combinations using RC220. Tillett noted that more updates on this work are expected in the coming months. Watch the full video to hear more from Daniel Tillett and stay informed on Race Oncology’s developments. ➡️ For more interviews like this, visit Proactive’s YouTube channel. Don’t forget to like the video, subscribe to the channel, and hit the notification bell for future updates. #RaceOncology #RC220 #CancerResearch #ClinicalTrials #OncologyUpdates #Doxorubicin #CardioProtection #BayesianDesign #CancerTreatment #BiotechNews #ProactiveInvestors

Gaming Realms PLC CEO Mark Segal takes Proactive's Stephen Gunnion through the company's strong 2024 financial performance and its ongoing international expansion. The company reported a year of strong growth, with revenue rising in both core content licensing and non-core social segments. Segal highlighted a “revenue increase, increase in our core content licensing business,” alongside gains in adjusted EBITDA and net profit, underlining operational leverage within the business. The company's flagship Slingo titles drove momentum, with 12 new releases in 2024 and North America contributing 54% of licensing revenue. “The cohorts of games we built in 2024 has probably been our highest-grossing sets of games in the first year,” said Segal. Gaming Realms is now live in five regulated U.S. states and recently launched in Brazil, aiming to deepen its presence in both. Segal also discussed the addition of third-party studio content, including Real Play, For The Player, and upcoming partner S Gaming, helping diversify offerings and penetrate high-barrier markets like the U.S. Cash generation remains strong, with a £13.5 million balance and a share buyback program underway. Looking ahead, Segal said the company expects continued organic growth, expansion into South Africa, and new launches with British Columbia’s lottery. Visit Proactive's YouTube channel for more investor-focused interviews. Don’t forget to like this video, subscribe to the channel, and enable notifications so you never miss an update. #GamingRealms #Slingo #OnlineGaming #iGaming #GamingStocks #GamingInvestments #NorthAmericaGaming #BrazilGamingMarket #DigitalGames #InvestorUpdate #CashGenerative #LicensingRevenue #StockMarketNews

Switch Metals Plc (AIM:SWT) CEO Karl Akueson talked with Proactive's Stephen Gunnion about the company’s listing on London’s AIM market and its focus on developing tantalum projects in Côte d'Ivoire. Akueson explained that Switch Metals, a private company he founded, was acquired through a reverse takeover by Oneiro Energy. The company's flagship Issia project hosts tantalum mineralisation, including occurrences of coltan at surface. According to Akueson, this provides an opportunity for near-term production from shallow deposits, with the company aiming to reach output within the next two years. He described tantalum as “a very strategic technology metal… in our mobile phones, laptops, plasma TV, everything we use daily,” highlighting its importance and rarity. Akueson emphasised that 60% of the global supply currently comes from the DRC and Rwanda, and Switch Metals aims to become a significant alternative source. Discussing the decision to list in the UK, Akueson pointed to his personal background and the UK’s long-standing understanding of African production. The £2 million fundraise will support resource definition work at Issia, with plans to quickly define a resource and develop economic parameters to demonstrate value. “Tantalum is probably one of the most critical [metals], and a metal that is unique,” Akueson noted. For more interviews and updates, visit Proactive’s YouTube channel. Don’t forget to like this video, subscribe, and enable notifications for future content. #Tantalum #SwitchMetals #CotedIvoireMining #CriticalMinerals #AIMListing #JuniorMining #ResourceDefinition #Coltan #TechMetals #ProactiveInvestors

Krakatoa Resources Ltd chairman Colin Locke talked with Proactive about the company’s newly secured Zopkhito Project in Georgia, which he described as a major opportunity for investors. The project contains a JORC resource of 225,000 tonnes of high-grade antimony at 11% for 26,000 tonnes of metal, translating to a back-of-the-envelope valuation of approximately $1.30 billion based on current prices. Additionally, the project includes 7.1 million tonnes grading 3.7g/t gold for 815,000 ounces, estimated to be worth around $2.50 billion. Locke said, “This is touted to be the sixth biggest antimony project in the world.” The mineralisation is close to surface, and the company believes the resource has strong potential for expansion. He also highlighted the project’s additional gold content as another value driver. He attributed the company’s success in securing the project to its CEO and chief technical officer, Mark Major, whose experience in high-altitude exploration was a key factor for the local vendors. The project’s location in Georgia was described as highly investor-friendly, with a 15% corporate tax rate, no native title or land access complications, and strong support for foreign investment. Locke confirmed that a maiden drilling program is scheduled to begin shortly, with Major heading to Georgia next week to prepare. He emphasised the company’s past success with international projects and reassured investors of the team’s experience. In closing, he noted the company's current market capitalisation of just AUD 5 million, suggesting significant upside. 👉 For more interviews like this, visit Proactive’s YouTube channel. Don’t forget to like the video, subscribe to the channel, and turn on notifications for future updates. #ProactiveInvestors #KrakatoaResources #ASX #gold #antimony